First-line immunotherapy in advanced non-small-cell lung cancer

Vanita Noronha; Prashant Mehta; Prabhat Singh Malik; Amol Patel

首页> 外文期刊>Indian Journal of Medical and Paediatric Oncology >First-line immunotherapy in advanced non-small-cell lung cancer

【24h】

First-line immunotherapy in advanced non-small-cell lung cancer

机译：先进非小细胞肺癌的一线免疫疗法

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Although immune checkpoint blockers (ICBs) were discovered in the 1990s, the initial reports of their efficacy in non-small-cell lung cancer (NSCLC) came through in 2012, whennivolumab (BMS-936558) showed responses in a Phase 1 study. From then on, there has been a constant flow of data pertaining ICBs in a multitude of previously treatedmalignancies.

机译：虽然在20世纪90年代发现了免疫检查点障碍物（ICB），但在2012年期间，当前潜水酸（BMS-936558）在2012年进行了初步报告，在2012年进行了1期研究。从那时起，在多个先前治疗的流动中存在恒定的数据流动。

著录项

来源
《Indian Journal of Medical and Paediatric Oncology》 |2019年第4期|共2页
作者
Vanita Noronha; Prashant Mehta; Prabhat Singh Malik; Amol Patel;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. PD-1 targeted Immunotherapy as first-line therapy for advanced non-small-cell lung cancer patients [J] . Arik Bernard Schulze, Lars Henning Schmidt Journal of Thoracic Disease . 2017,第4期

机译：PD-1靶向免疫疗法作为晚期非小细胞肺癌患者的一线治疗
2. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial [J] . Quoix Elisabeth, Lena Herve, Losonczy Gyorgy, The lancet oncology . 2016,第2期

机译：TG4010用于晚期非小细胞肺癌（TIME）的免疫疗法和一线化疗：来自随机，双盲，安慰剂对照，2b / 3期试验的2b期结果
3. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease [J] . Besse B., Adjei A., Baas P., Annals of oncology: official journal of the European Society for Medical Oncology . 2014,第8期

机译：第二届ESMO肺癌共识会议：非小细胞肺癌一线/二线及其他晚期疾病的治疗方法
4. Effects of Erlotinib after Acquired Resistance to Gefitinib in Advanced Non-small-cell Lung Cancer [C] . Pan Jingjing, Shi Meiqi, Feng Jifeng Biomedical Engineering and Biotechnology (iCBEB), 2012 International Conference on . 2012

机译：吉非替尼耐药对晚期非小细胞肺癌患者的厄洛替尼治疗效果
5. Pharmacology Profiles of ALK and FLT3 Kinase Inhibitors against Non-Small-Cell Lung Cancer Cells and Acute Myeloid Leukemia Cells with Cancer Driver Mutations [D] . 森政道 2019

机译：ALK和FLT3激酶抑制剂对非小细胞肺癌细胞和急性髓系白血病细胞的癌症驱动突变的药理作用
6. Efficacy of Combination Chemo-Immunotherapy as a First-Line Treatment for Advanced Non-Small-Cell Lung Cancer Patients With HER2 Alterations: A Case Series [O] . Shuang Zhao, Xinghong Xian, Panwen Tian, 2021

机译：联合化疗 - 免疫疗法作为患有HER2改变的先进非小细胞肺癌患者的一线治疗的疗效：案例系列
7. Efficacy of Combination Chemo-Immunotherapy as a First-Line Treatment for Advanced Non-Small-Cell Lung Cancer Patients With HER2 Alterations: A Case Series [O] . Shuang Zhao, Xinghong Xian, Panwen Tian, 2021

机译：联合化疗 - 免疫疗法作为患有HER2改变的先进非小细胞肺癌患者的一线治疗的疗效：案例系列

First-line immunotherapy in advanced non-small-cell lung cancer

摘要

著录项

相似文献

相关主题

期刊订阅